Table 2 Univariate and multivariate analysis of clinico-pathological parameters for the prediction of cancer-specific survival in patients with inoperable pancreatic cancer (n=261)
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
Parameter | HR (95% CI) | P -value | HR (95% CI) | P -value |
Gender | ||||
Female | 1 (referent) | 0.383 | 1 (referent) | 0.850 |
Male | 0.893(0.693–1.151) | 1.033 (0.734–1.455) | ||
Age at diagnosis (years) | ||||
<65 | 1 (referent) | 0.118 | 1 (referent) | 0.061 |
⩾65 | 1.221 (0.950–1.570) | 0.72 (0.511–1.015) | ||
Stage at diagnosis | ||||
Locally advanced | 1 (referent) | <0.001 | 1 (referent) | 0.002 |
Metastatic | 1.972 (1.390–2.797) | 2.194 (1.326–3.631) | ||
Treatment | ||||
No chemotherapy | 1 (referent) | <0.001 | 1 (referent) | 0.001 |
Chemotherapeutic treatment | 0.751 (0.686–0.823) | 0.801 (0.703–0.913) | ||
Neutrophil-lymphocyte ratio | ||||
<5 | 1 (referent) | <0.001 | 1 (referent) | <0.001 |
⩾5 | 2.193 (1.664–2.889) | 2.532 (1.640–3.910) | ||
Glasgow prognostic score | ||||
0 | 1 (referent) | 0.029 | 1 (referent) | 0.319 |
1+2 | 1.437 (1.038–1.989) | 1.201 (0.838–1.720) | ||
Platelet-lymphocyte ratio | ||||
<150 | 1 (referent) | 0.612 | NI | |
⩾150 | 1.071 (0.822–1.396) | |||
